Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $13,822,739.60 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Gilead Sciences Trading Up 1.2 %

Shares of NASDAQ:GILD traded up $1.18 during trading on Monday, hitting $98.38. 10,509,697 shares of the company’s stock were exchanged, compared to its average volume of 7,014,780. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $99.45. The firm has a 50-day moving average price of $92.42 and a two-hundred day moving average price of $85.96. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market cap of $122.61 billion, a P/E ratio of 1,093.11, a PEG ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the company earned $2.29 EPS. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. Equities analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in Gilead Sciences during the third quarter valued at approximately $25,000. HHM Wealth Advisors LLC grew its holdings in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC grew its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $28,000. Finally, Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Truist Financial raised their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, UBS Group raised their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.